Udvalget for Humanmedicinske Lægemidler (CHMP) vurderede, at fordelene ved MicardisPlus er større end risiciene til behandling af essentiel hypertension hos patienter, hvis blodtryk ikke er tilstrækkeligt under kontrol med telmisartan alene.
The Committee for Medicinal Products for Human Use (CHMP) decided that MicardisPlus’ s benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on telmisartan alone.